Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Polyrizon Ltd. - Ordinary Shares (NQ:PLRZ)

10.55 -0.22 (-2.04%)
Streaming Delayed Price Updated: 3:06 PM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,158
Open 10.50
Bid (Size) 10.25 (300)
Ask (Size) 11.00 (200)
Prev. Close 10.77
Today's Range 10.40 - 10.76
52wk Range 2.880 - 18.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
From Polyrizon Ltd.
Via GlobeNewswire

Performance

YTD
-17.3%
-17.3%
1 Month
-19.7%
-19.7%
3 Month
-17.3%
-17.3%
6 Month
-11.2%
-11.2%
1 Year
+55.6%
+55.6%

More News

Read More
News headline image
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
From Polyrizon Ltd.
Via GlobeNewswire
PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗
Via Stocktwits
News headline image
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
TechMediaBreaks – Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement
Via Investor Brand Network
News headline image
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Provides 2025 and Recent Highlights
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
From Polyrizon Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Polyrizon Ltd. - Ordinary Shares publicly traded?
Yes, Polyrizon Ltd. - Ordinary Shares is publicly traded.
What exchange does Polyrizon Ltd. - Ordinary Shares trade on?
Polyrizon Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Polyrizon Ltd. - Ordinary Shares?
The ticker symbol for Polyrizon Ltd. - Ordinary Shares is PLRZ on the Nasdaq Stock Market
What is the current price of Polyrizon Ltd. - Ordinary Shares?
The current price of Polyrizon Ltd. - Ordinary Shares is 10.55
When was Polyrizon Ltd. - Ordinary Shares last traded?
The last trade of Polyrizon Ltd. - Ordinary Shares was at 09/28/26 03:06 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.